These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Estrogens in the treatment of Basedow's disease and its complications]. GUINET P J Med Lyon; 1950 Apr; 31(727):341-51. PubMed ID: 15412325 [No Abstract] [Full Text] [Related]
24. [Goiter and thyroid pathology in Belgium; a new case of Basedow's disease treated with radioactive iodine]. BRULL L; LEFEBVRE L Rev Med Liege; 1950 Jul; 5(13):353-7. PubMed ID: 15430775 [No Abstract] [Full Text] [Related]
25. [BASEDOW'S DISEASE: RESULTS OF 680 TREATMENTS WITH I-131]. BRAKIER T; MERCHIE G; BRULL L; NIZET A Nucl Med (Stuttg); 1963 Oct; 3():241-50. PubMed ID: 14100343 [No Abstract] [Full Text] [Related]
26. [DATA ON THE FEEDBACK MECHANISM IN HYPERTHYROIDISM AND BASEDOW'S DISEASE]. NEGOESCU I; BALAN M; STANCU H; VOICULET N; PETRESCU C Stud Cercet Endocrinol; 1964; 15():547-53. PubMed ID: 14338531 [No Abstract] [Full Text] [Related]
27. [Effects of methylthiouracil and aminothiazole in preoperative therapy in Basedow's disease and thyreotoxicosis]. SIMIC S Srp Arh Celok Lek; 1950 Mar; 48(3):202-10. PubMed ID: 15442717 [No Abstract] [Full Text] [Related]
29. [IMPORTANCE OF SEDATIVE TREATMENT IN BASEDOW'S DISEASE]. MERCHIE G; BRAKIER T Rev Med Liege; 1964 Nov; 19():663-6. PubMed ID: 14223391 [No Abstract] [Full Text] [Related]
30. [For X-ray treatment of Graves' disease]. TOPPNER R Strahlentherapie; 1947; 77(1):55-62. PubMed ID: 18907389 [No Abstract] [Full Text] [Related]
31. [Relations of cholesterol in myxedema and in the hypercholesterinemia of treated Basedow's disease]. MAHAUX J Acta Clin Belg; 1950; 5(3):292-4. PubMed ID: 15432034 [No Abstract] [Full Text] [Related]
32. [LONG TERM RESULTS OF TREATMENT OF BASEDOW'S DISEASE WITH RADIOACTIVE IODINE]. LINQUETTE M; SWYNGEDAUW J; MAY JP Lille Med; 1964 Dec; 9():903-5. PubMed ID: 14260262 [No Abstract] [Full Text] [Related]
33. MANAGEMENT OF THYROTOXICOSIS IN PATIENTS WITH OPHTHALMOPATHY: ANTITHYROID REGIMEN DETERMINED PRIMARILY BY OCULAR MANIFESTATIONS. ARANOW H; DAY RM J Clin Endocrinol Metab; 1965 Jan; 25():1-10. PubMed ID: 14252283 [No Abstract] [Full Text] [Related]
34. [PARADOXAL WEIGHT GAIN IN BASEDOW'S DISEASE]. LAUBIE B; LATAPIE JL; MOREAU F; RIVIERE J J Med Bord; 1965 Mar; 142():415-22. PubMed ID: 14306779 [No Abstract] [Full Text] [Related]
35. [BASEDOW'S DISEASE OF LONG INITIAL DIENCEPHALIC PHASE WITH OBESITY]. LAUBIE E; LAUBIE B J Med Bord; 1963 Sep; 140():1345-9. PubMed ID: 14090756 [No Abstract] [Full Text] [Related]
36. [Principles in the treatment of Graves-Basedow's disease]. TUSZKIEWICZ AR Pol Tyg Lek (Wars); 1951 Feb; 6(7):211-9. PubMed ID: 14864134 [No Abstract] [Full Text] [Related]
37. THE EYE SIGNS OF GRAVES' DISEASE. LEBENSOHN JE Am J Ophthalmol; 1964 Apr; 57():680-1. PubMed ID: 14139314 [No Abstract] [Full Text] [Related]
39. [Effect of guanethidine eyedrops on the ocular manifestations of Basedow's disease]. Berkman N; Joseph E Arch Ophtalmol Rev Gen Ophtalmol; 1971; 31(8):617-28. PubMed ID: 4256931 [No Abstract] [Full Text] [Related]
40. [The replacement of the flavinfosphoric ester in Graves' disease]. DE CANDIA S; PELOSIO C Policlinico Prat; 1948; 55(11-12):227-34. PubMed ID: 18116408 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]